Compass Therapeutics' stock (CMPX) dropped sharply, with reports of 60% decline to $2.06, 80% fall, and 14.5% to $1.62 following announcement of Phase 2/3 COMPANION-002 trial results123.
Tovecimig combined with paclitaxel missed the overall survival (OS) secondary endpoint (8.9 months vs. 9.4 months, p=0.78), due to high crossover (54% from control arm) complicating analysis; RPSFT adjustment also showed no benefit (p=0.65) and results uninterpretable1.
Tovecimig met primary progression-free survival (PFS) endpoint with median 4.7 months vs. 2.6 months for paclitaxel alone (56% risk reduction), and statistically significant overall response rate of 17.1% vs. 5.3% (p=0.031)1.
Analysts at William Blair note data shows clinical benefit but raises FDA approvability questions amid investor uncertainty1.
Trial involved second-line biliary tract cancer patients receiving tovecimig plus paclitaxel15.
Sources:
1. https://www.benzinga.com/markets/biotech/26/04/52068618/compass-therapeutics-drops-sharply-as-trial-crossover-complicates-survival-data-in-bile-duct-cancer-patients
2. https://www.investing.com/news/stock-market-news/compass-therapeutics-stock-tumbles-after-trial-data-93CH-4638650
3. https://de.tradingview.com/news/reuters.com,2025:newsml_L3N3QF10U:0-compass-therapeutics-falls-brokerage-says-cancer-drug-trial-data-underwhelms/
5. https://www.investing.com/news/stock-market-news/compass-therapeutics-stock-plunges-on-trial-data-concerns-william-blair-comments-93CH-4638660